Application of stereotactic body radiation therapy in advanced renal cell carcinoma %0 Journal Article %D 2019 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2019.10.013 %P 627-630 %V 46 %N 10 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10717.shtml} %8 2019-10-08 %X

Stereotactic body radiation therapy (SBRT) can effectively kill renal cancer cells by biological molecules such as hypoxia-inducible factor-1αand acid sphingomyelinase. SBRT regimen withhigher biological dose and single irradiation can achieve more effective local control of primary and metastatic lesion of advanced renal cancer, and adverse reactions can be tolerated. Combination of SBRT and targeted drugs can increase the sensitivity of renal cancer to radiotherapy, and the combination of SBRT and immune drugs can enhance the immune response through the abscopal effect. The efficacy of SBRT in the treatment of advanced renal cancer remains to be explored.